PROCTER-&-GAMBLE
20.7.2021 10:02:14 CEST | Business Wire | Press release
P&G unveils its first paper bottle for Lenor in partnership with paper bottle company Paboco, announcing a pilot for Western Europe in 2022. The trial rollout will form the basis of a test and learn strategy to scale up paper packaging and incorporate it more widely across P&G’s portfolio.
P&G Fabric & Home Care with its popular brands including Ariel, Lenor, Tide, Downy, Fairy, and Cascade is fully committed to reducing plastics in its packaging. As part of its 2030 Ambition, P&G aims to reduce its use of virgin plastics by 50% by 2030. Fabric Care Europe has additionally committed to a 30% absolute plastics reduction by 2025 and to design for 100% recyclability by 2022 - it is well on track for both commitments. Home Care is committed to use no virgin plastics by 2025. Brand-led packaging alternatives and pilot schemes are a crucial element in the pathways to lowering environmental impact.
Paboco’s paper bottle technology is advancing quickly and promises to reduce and replace plastic content while lowering carbon footprint compared to conventional plastic packaging. This alternative form of packaging is increasingly viable and scaling at pace, backed by leading consumer goods companies and industry experts including The Coca-Cola Company, Carlsberg Group, The Absolut Company, L’Oréal, BillerudKorsnäs, and ALPLA united by the vision to create the world's first 100% bio-based and recyclable paper bottle at scale.
Senior Vice President of R&D for Global Fabric & Home Care Sector Jerry Porter explains:
“We’re very excited to join this group of packaging innovators. This is another milestone on our P&G Fabric & Home Care journey to innovate towards more sustainable packaging formats. Our chosen pilot brand Lenor has a great track record of incorporating recycled plastic into its packaging, already using up to 100% in its European transparent bottles. Now we aim to go a step further with bio-based packaging, which has a very promising future. We are delighted to be on this journey with our partners in the development of the next generations of paper bottles.”
Speaking on behalf of Paboco, interim CEO Gittan Schiöld noted:
“Our vision is to change this industry for good, and to create a world less dependent on plastic and without plastic waste, by designing for circularity and inventing packaging from bio-based materials. Storing liquids in paper is particularly challenging, but its successful adoption could have major benefits for the planet. Having P&G Fabric & Home Care category as a partner in the paper bottle community is a huge boost to that vision. Not only does it really add weight to the viability of the technology but brings with it P&G’s know-how to the table, offering new opportunities for scaling Paboco’s paper bottle technology.”
Lenor’s first paper bottle is a step on the bio-based packaging journey. The bottle already significantly reduces plastic compared to a bottle used today. The bottle is the first of its kind produced at scale, in its design and technology, made from sustainably sourced FSC-certified paper and initially a thin plastic barrier made from post-consumer recycled PET. Building on learnings from this milestone, future versions of the bottle will integrate the barrier into the paper lining to create a seamless, 100% bio-based bottle, fully recyclable in the paper stream.
All of P&G’s leadership brands, including Lenor, are expected to inspire responsible consumption by 2030 as part of the company’s Ambition 2030 sustainability goals.
To access images and other multimedia content, please visit here .
ENDS
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005201/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom